VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients with a confirmed diagnosis of             │ Patients with a confirmed diagnosis of             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stage 4 colon cancer either s/p metastasectomy or  │ Stage 4 colon cancer either s/p metastasectomy or  │     100 │
│ post-initial chemotherapy or maintenance "standard │ post-initial chemotherapy or maintenance "standard │         │
│ of care", either involving                         │ of care", either involving                         │         │
│ 5-fluorouracil/leucovorin (5-FU/LV) alone or       │ 5-fluorouracil/leucovorin (5-FU/LV) alone or       │         │
│ continual bevacizumab alone. Patients in           │ continual bevacizumab alone. Patients in           │         │
│ maintenance cohort must have had 2 consecutive CT  │ maintenance cohort must have had 2 consecutive CT  │         │
│ scans showing stable disease and not be            │ scans showing stable disease and not be            │         │
│ experiencing significant prior treatment-related   │ experiencing significant prior treatment-related   │         │
│ toxicity above Grade 1                             │ toxicity above Grade 1                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pancreas cancer, either s/p resection and adjuvant │ Pancreas cancer, either s/p resection and adjuvant │     100 │
│ chemotherapy or locally advanced pancreas cancer   │ chemotherapy or locally advanced pancreas cancer   │         │
│ s/p chemotherapy and radiation. Initial            │ s/p chemotherapy and radiation. Initial            │         │
│ chemotherapy or radiation therapy may have been    │ chemotherapy or radiation therapy may have been    │         │
│ stopped between 2 weeks and 2 months prior to      │ stopped between 2 weeks and 2 months prior to      │         │
│ study start, and patients must have recovered from │ study start, and patients must have recovered from │         │
│ prior treatment related toxicity to grade 1 or     │ prior treatment related toxicity to grade 1 or     │         │
│ less                                               │ less                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior surgery, including tumor resection or        │ Prior surgery, including tumor resection or        │     100 │
│ metastasectomy must have been performed at least 4 │ metastasectomy must have been performed at least 4 │         │
│ weeks prior to study enrollment                    │ weeks prior to study enrollment                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No concomitant anti-cancer treatment is allowed    │ No concomitant anti-cancer treatment is allowed    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Performance status of 0-1                          │ Performance status of 0-1                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adequate hepatic, bone marrow, and renal function  │ Adequate hepatic, bone marrow, and renal function  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of childbearing potential must have a        │ Women of childbearing potential must have a        │     100 │
│ negative serum pregnancy test within 14 days prior │ negative serum pregnancy test within 14 days prior │         │
│ to initiation of treatment and must not be         │ to initiation of treatment and must not be         │         │
│ lactating                                          │ lactating                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject is capable of understanding and complying  │ Subject is capable of understanding and complying  │     100 │
│ with protocol demands and able to sign and date    │ with protocol demands and able to sign and date    │         │
│ the informed consent                               │ the informed consent                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of child-bearing potential, who are          │ Women of child-bearing potential, who are          │     100 │
│ biologically able to conceive, not employing two   │ biologically able to conceive, not employing two   │         │
│ forms of highly effective contraception or who are │ forms of highly effective contraception or who are │         │
│ pregnant                                           │ pregnant                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are breast-feeding                       │ Women who are breast-feeding                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fertile males unwilling to use contraception       │ Fertile males unwilling to use contraception       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with brain metastases or any history of   │ Patients with brain metastases or any history of   │     100 │
│ brain metastases                                   │ brain metastases                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have undergone major surgery (e.g.,   │ Patients who have undergone major surgery (e.g.,   │     100 │
│ intra-thoracic, -abdominal, or -pelvic) \</= 4     │ intra-thoracic, -abdominal, or -pelvic) </= 4      │         │
│ weeks prior to starting study treatment or who     │ weeks prior to starting study treatment or who     │         │
│ have not recovered from such therapy               │ have not recovered from such therapy               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a history of pulmonary embolism, or  │ Patients with a history of pulmonary embolism, or  │     100 │
│ untreated deep vein thrombosis within the past 6   │ untreated deep vein thrombosis within the past 6   │         │
│ months                                             │ months                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Impairment of gastrointestinal (GI) function or GI │ Impairment of gastrointestinal (GI) function or GI │     100 │
│ disease that may significantly alter the           │ disease that may significantly alter the           │         │
│ absorption of dovitinib                            │ absorption of dovitinib                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The subject has had another active malignancy      │ The subject has had another active malignancy      │     100 │
│ within the past 5 years except for cervical cancer │ within the past 5 years except for cervical cancer │         │
│ in situ, in situ carcinoma of the bladder or non-  │ in situ, in situ carcinoma of the bladder or non-  │         │
│ melanoma carcinoma of the skin                     │ melanoma carcinoma of the skin                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have received the last administration │ Patients who have received the last administration │     100 │
│ of an anticancer therapy including chemotherapy,   │ of an anticancer therapy including chemotherapy,   │         │
│ immunotherapy, hormonal therapy and monoclonal     │ immunotherapy, hormonal therapy and monoclonal     │         │
│ antibodies \</= 2 weeks prior to starting the      │ antibodies </= 2 weeks prior to starting the study │         │
│ study drug, or who have not recovered from the     │ drug, or who have not recovered from the side      │         │
│ side effects of such therapy                       │ effects of such therapy                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cirrhosis, chronic active hepatitis or chronic     │ Cirrhosis, chronic active hepatitis or chronic     │     100 │
│ persistent hepatitis                               │ persistent hepatitis                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are currently receiving prasugrel     │ Patients who are currently receiving prasugrel     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No concurrent use of isoniazid, labetolol,         │ No concurrent use of isoniazid, labetolol,         │     100 │
│ trovafloxacin, tolcapone, and felbamate            │ trovafloxacin, tolcapone, and felbamate            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No concurrent use of other investigational drugs   │ No concurrent use of other investigational drugs   │     100 │
│ or antineoplastic therapies                        │ or antineoplastic therapies                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with impaired cardiac function or         │ Patients with impaired cardiac function or         │     100 │
│ clinically significant cardiac diseases            │ clinically significant cardiac diseases            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age \>/= 18 years                                  │ Age >/= 18 years                                   │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Partial thromboplastin time (PTT) must be \</= 1.5 │ Partial thromboplastin time (PTT) must be </= 1.5  │      99 │
│ x upper normal limit of institution's normal range │ x upper normal limit of institution's normal range │         │
│ and INR (International Normalized Ratio) \< 1.5    │ and INR (International Normalized Ratio) < 1.5     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy \>/= 4 months for maintenance      │ Life expectancy >/= 4 months for maintenance       │      99 │
│ cohorts and \>/= 6 months for adjuvant cohorts     │ cohorts and >/= 6 months for adjuvant cohorts      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria    │   Score │
╞═══════════════════════════════════╪══════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age >/= 18 years │      45 │
╘═══════════════════════════════════╧══════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.77777777777777
OverAll Ratio: 98.38888888888889
